Pre-quotation disclosure statement
Released
Released
Announcement PDF
Biome Australia Limited
ABN: 51 627 364 014
16 Dover Street, Cremorne VIC 3121
+61 3 9017 5800 | www.biomeaustralia.com
FOR IMMEDIATE RELEASE
Satisfaction of Listing
Conditions
Melbourne, Victoria, 30 November 2021 – complementary medicines company, Biome Australia Limited
(Biome Australia) confirms that it has satisfied each of the Conditions to Admission as detailed in the
Admission Decision dated 18 November 2021.
Biome Australia provides the following pre-quotation disclosures:
The conversion of Performance Rights and issue of Options
The issue of the following securities:
Securities
Detail
Number
Ordinary Shares
The 11,175,907 Performance Rights have been converted into
11,175,907 Ordinary Shares.
11,175,907 Ordinary
Shares
2,131,404 options have been issued with an exercise price of $0.30
exercisable for a period of three years from the date of issue to a
controlled entity of Canaccord Genuity (Australia) Limited
2,131,404 Options
2,131,404 options with an exercise price of $0.40 exercisable for a
period of four years from the date of issue to a controlled entity of
Canaccord Genuity (Australia) Limited
2,131,404 Options
Options
ASX imposed escrow
The following Shares and Options are subject to ASX restrictions:
2
Security
Number
ASX restriction period
Ordinary Shares
39,359,545
24 months commencing on the date of official quotation of
the ordinary shares in Biome Australia
Ordinary Shares
718,842
Ending on 11 January 2022
415,582
Ending on 1 March 2022
506,336
Ending on 12 March 2022
16,848
Ending on 19 March 2022
126,290
Ending on 26 March 2022
89,856
Ending on 29 March 2022
251,595
Ending on 26 April 2022
336,958
Ending on 13 May 2022
224,638
Ending on 1 June 2022
112,319
Ending on 11 June 2022
28,107
Ending on 15 June 2022
224,638
Ending on 16 June 2022
188,697
Ending on 18 June 2022
224,638
Ending on 21 June 2022
494,203
Ending on 22 June 2022
1,120,652
Ending on 23 June 2022
Options
224,638
Ending on 28 June 2022
112,319
Ending on 30 June 2022
224,638
Ending on 19 July 2022
560,696
Ending on 20 July 2022
22,464
Ending on 26 July 2022
33,696
Ending on 27 July 2022
44,928
Ending on 29 July 2022
20,218
Ending on 30 July 2022
112,319
Ending on 4 August 2022
1,213,498
Ending on 5 August 2022
65,236
Ending on 6 August 2022
134,783
Ending on 9 August 2022
151,631
Ending on 10 August 2022
60,653
Ending on 11 August 2022
101,088
Ending on 12 August 2022
22,464
Ending on 13 August 2022
56,160
Ending on 15 August 2022
179,801
Ending on 16 August 2022
325,726
Ending on 18 August 2022
381,885
Ending on 31 August 2022
4,401,865
24 months commencing on the date of official quotation of
the ordinary shares in Biome Australia
Voluntary escrow
The following Shares are subject to voluntary escrow:
3
Security
Number
ASX restriction period
Ordinary Shares
47,470,727
Ending 6 months following the date of quotation, being 31 May 2022
Biome Australia's capital deck
The capital deck of Biome Australia is as follows:
Security
Number
Ordinary Shares
199,909,857 Ordinary Shares. This is made up of:
● 148,733,950 Existing Shares;
● 40,000,000 Shares issued under the Offer; and
● 11,175,907 Shares issued on conversion of Performance Rights.
Options
17,261,659 Options. This is made up of:
● 12,998,851 Existing Options; and
● 4,262,808 Options issued to a controlled entity of the Lead Manager, Canaccord Genuity
(Australia) Limited.
Authorised for release by the Board of Biome Australia Limited.
About Biome Australia Limited
Biome Australia
Biome Australia develops, licenses, commercialises innovative, evidence-based live biotherapeutics
(probiotics) and complementary medicines, many of which are supported by clinical research. Biome aims
to improve health outcomes and quality of life, and make its products accessible to all.
Incorporated in Australia in 2018, Biome distributes locally and abroad. In partnership with some of the
world's leading organisations in microbiome research and development, Biome produced several unique
live biotherapeutic (probiotic) products with innovative delivery technologies that improve their stability and
efficacy to create its flagship range of complementary medicines: Activated Probiotics®.
Supported by clinical research, including randomised double-blind placebo-controlled trials, Activated
Probiotics help prevent and support the management of various health concerns, including low mood and
sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner-only distribution, Biome
is committed to educating health professionals on the newfound systemic health effects of the gut
microbiota, helping them to provide innovative, evidence-based natural medicines for the management of
some of humanity's most prevalent and chronic health concerns.
Biome also develops, licenses and distributes a scientifically formulated, organic nutraceutical range,
Activated Nutrients® and a sports performance and recovery range, Activated X Performance®, which is
made exclusively for professional athletes.
For more information visit: www.biomeaustralia.com
For further information, please contact:
George Lazarou
Company Secretary
T: (03) 8617 8014
E: george@activated.co
4
Share your feedback
Discover